The RheumNow Week in Review – 9 June 2017 Save

Dr. Jack Cush reviews the news and reports of interest from RheumNow in the last week:

1. Abbvie Scholarship program accepting applications to award 15 grants ($15k/yr) to Students with Rheumatic disorders https://t.co/lgDLQRznJN
2. Using Claims data, Allopurinol associated with lower risk of incident renal disease (HR 0.61) compared to febuxostat https://t.co/iGUKB4MxK0
3. SLE myositis more likely to have rash, alopecia, pericarditis, vasculitis, Sm, RNP, dsDNA, low Plts & WBC, low C3.C4 https://t.co/UwWVr1XuhY
4. Autoimmune diseases w/ MYOCARDITIS include sarcoidosis, Behçets, Churg-Strauss, inflammatory myositis, SLE https://t.co/zb3LdzUL9G
5. QUEST-RA study shows the average RA pt has 2+ comorbidities (HTN, OP,OA); fatigue assoc w/ comorbidity & dz activity https://t.co/BPTsGW82ho
6. Retro review of open label Tofacitinib 5 mg bid in 13 pts w/ alopecia areata showing ~50% regrowth after 4-5 mos https://t.co/Umw6vCOp3j
7. Case reports showing tofacitinib, ruloxocitinb efficacy in difficult dermatomyositis, leads makers of JAK inhibitors to consider RCTs in DM
8. Metormins effx mediated by change in gut microbiome; transfer of metformin-altered microbiota improves Glu tolerance https://t.co/1HvCnS19kW
9. FDA Requests Removal of OPANA-ER from the Market 
10. Debate over Alcohol and Methotrexate Precautions 
11. Biosimilar Reports – May 2017
12. Higher Fracture Risks with Prolonged Bisphosphonate Use in Older Women